For more on this story: https://xtalks.com/amtagvi-lifileucel-scores-landmark-win-as-first-fda-approved-t-cell-therapy-for-a-solid-tumor-3747/
Iovance’s Amtagvi has become the first FDA-approved T-cell therapy for a solid tumor and the first approved TIL immunotherapy. Amtagvi is approved for the treatment of unresectable or metastatic melanoma. In clinical trials, Amtagvi was shown to have a 31.5 percent response rate, with 43.5 percent of responders continuing to maintain responses for over one year.
#CellandGeneTherapy #CARTCellTherapy #CellTherapy #Immunotherapy #Oncology #Cancer #CancerDrug #FDA #FDAApproval #Melanoma #SolidTumor #SkinCancer